Cephalosporin resistance, tolerance, and approaches to improve their activities | The Journal of Antibiotics - Nature.com

Abstract

Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

References

  1. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999;74:187–95.

    Article  PubMed  CAS  Google Scholar 

  2. Brotzu G. Research on a new antibiotic. Cagliari Inst Hyg. 1948;1:5–15.

    Google Scholar 

  3. Newton GG, Abraham EP. Cephalosporin C, a new antibiotic containing sulphur and D-alpha-aminoadipic acid. Nature. 1955;175:548.

    Article  ADS  PubMed  CAS  Google Scholar 

  4. Abraham EP. Cephalosporins 1945–1986. Drugs. 1987;34:1–14.

    Article  PubMed  CAS  Google Scholar 

  5. Chauvette RR, et al. Chemistry of Cephalosporin Antibiotics .2. Preparation of a new class of antibiotics and relation of structure to activity. J Am Chem Soc. 1962;84:3401.

    Article  CAS  Google Scholar 

  6. Godzeski CW, Brier G, Pavey DE. Cephalothin, a new cephalosporin with a broad antibacterial spectrum. I. In vitro studies employing the gradient plate technique. Appl Microbiol. 1963;11:122–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Griffith RS, Black HR. Cephalothin-a new antibiotic. Preliminary clinical and laboratory studies. JAMA. 1964;189:823–8.

    Article  PubMed  CAS  Google Scholar 

  8. Chang TW, Weinstein L. In vitro biological activity of cephalothin. J Bacteriol. 1963;85:1022–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. WHO model list of essential medicines - 22nd list. World Health Organization, Document: WHO/MHP/HPS/EML/2021.02 (2021).

  10. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. World Health Organization, Document: ISBN 978-92-4-006238-2 (2022).

  11. Goldstein E. Rise in the prevalence of resistance to extended-spectrum cephalosporins in the USA, nursing homes and antibiotic prescribing in outpatient and inpatient settings. J Antimicrob Chemother. 2021;76:2745–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Penalva G, et al. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019;24:1900656.

  13. Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results? Comment. Lancet Microbe. 2021;2:E648–E649.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect Dis. 2021;21:597–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Jia X, et al. Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia. Int J Antimicrob Agents. 2020;55:105832.

    Article  PubMed  CAS  Google Scholar 

  16. Kishii K, Ito T, Watanabe S, Okuzumi K, Hiramatsu K. Recurrence of heterogeneous methicillin-resistant Staphylococcus aureus (MRSA) among the MRSA clinical isolates in a Japanese university hospital. J Antimicrob Chemother. 2008;62:324–8.

    Article  PubMed  CAS  Google Scholar 

  17. Ma W, Sun J, Yang S, Zhang L. Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China. Eur J Clin Microbiol Infect Dis. 2016;35:571–8.

    Article  PubMed  CAS  Google Scholar 

  18. Bryson D, Hettle AG, Boraston AB, Hobbs JK. Clinical mutations that partially activate the stringent response confer multidrug tolerance in Staphylococcus aureus. Antimicrob Agents Ch. 2020;64:e02103–19.

    Article  CAS  Google Scholar 

  19. Hamad MA, Austin CR, Stewart AL, Higgins M, Vazquez-Torres A, Voskuil MI. Adaptation and Antibiotic tolerance of anaerobic Burkholderia pseudomallei. Antimicrob Agents Ch. 2011;55:3313–23.

    Article  CAS  Google Scholar 

  20. Hemsley CM, Luo JX, Andreae CA, Butler CS, Soyer OS, Titball RW. Bacterial drug tolerance under clinical conditions is governed by anaerobic adaptation but not anaerobic respiration. Antimicrob Agents Ch. 2014;58:5775–83.

    Article  Google Scholar 

  21. Zhang SS, Liu S, Wu N, Yuan YH, Zhang WH, Zhang Y. Small non-coding RNA RyhB mediates persistence to multiple antibiotics and stresses in Uropathogenic Escherichia coli by reducing cellular metabolism. Front Microbiol. 2018;9:1–10.

    Google Scholar 

  22. Abraham EP. A glimpse of the early history of the cephalosporins. Rev Infect Dis. 1979;1:99–105.

    Article  PubMed  CAS  Google Scholar 

  23. Bo G. Giuseppe Brotzu and the discovery of cephalosporins. Clin Microbiol Infect. 2000;6:6–9.

    Article  PubMed  Google Scholar 

  24. Brakhage AA. Molecular regulation of beta-lactam biosynthesis in filamentous fungi. Microbiol Mol Biol Rev. 1998;62:547–85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Hu Y, Zhu B. Study on genetic engineering of Acremonium chrysogenum, the cephalosporin C producer. Synth Syst Biotechnol. 2016;1:143–9.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Abraham E. Selective reminiscences of beta-lactam antibiotics: early research on penicillin and cephalosporins. Bioessays. 1990;12:601–6.

    Article  PubMed  CAS  Google Scholar 

  27. Abraham EP, Newton GGF, Hale CW. Purification and some properties of Cephalosporin-N, a new Penicillin. Biochem J. 1954;58:94–102.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Hamilton-Miller JMT. Sir Edward Abraham's contribution to the development of the cephalosporins: a reassessment. Int J Antimicrob Ag. 2000;15:179–84.

    Article  CAS  Google Scholar 

  29. Hamilton-Miller JMT. The cephalosporins and Sir Edward Abraham: Recollections about a great scientist and his part in the discovery of these antibiotics. J Antibiot. 2000;53:1003–7.

    Article  CAS  Google Scholar 

  30. Hodgkin DC, Maslen EN. The x-ray analysis of the structure of cephalosporin C. Biochem J. 1961;79:393–402.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Elks J. Structural formulae and nomenclature of the cephalosporin antibiotics. Drugs. 1987;34:240–6.

    Article  PubMed  Google Scholar 

  32. Lin XM, Kuck U. Cephalosporins as key lead generation beta-lactam antibiotics. Appl Microbiol Biot. 2022;106:8007–20.

    Article  CAS  Google Scholar 

  33. Byford MF, Baldwin JE, Shiau CY, Schofield CJ. The mechanism of ACV Synthetase. Chem Rev. 1997;97:2631–50.

    Article  PubMed  Google Scholar 

  34. Baldwin JE, Gagnon J, Ting HH. N-Terminal Amino-acid sequence and some properties of Isopenicillin-N Synthetase from Cephalosporium-Acremonium. Febs Lett. 1985;188:253–6.

    Article  PubMed  CAS  Google Scholar 

  35. Pang CP, et al. Purification of isopenicillin N synthetase. Biochem J. 1984;222:789–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Randall CR, et al. X-ray-absorption studies of the ferrous active-site of Isopenicillin N-Synthase and related model complexes. Biochem-Us. 1993;32:6664–73.

    Article  CAS  Google Scholar 

  37. Roach PL, et al. Structure of isopenicillin N synthase complexed with substrate and the mechanism of penicillin formation. Nature. 1997;387:827–30.

    Article  ADS  PubMed  CAS  Google Scholar 

  38. Ullan RV, Casqueiro J, Banuelos O, Fernandez FJ, Gutierrez S, Martin JF. A novel epimerization system in fungal secondary metabolism involved in the conversion of isopenicillin N into penicillin N in Acremonium chrysogenum. J Biol Chem. 2002;277:46216–25.

    Article  PubMed  CAS  Google Scholar 

  39. Brewer SJ, Farthing JE, Turner MK. The oxygenation of the 3-methyl group of 7beta-(5-D-aminoadipamido)-3-methylceph-3-em-4-carboxylic acid (desacetoxycephalosporin C) by extracts of Acremonium chrysogenum [proceedings]. Biochem Soc Trans. 1977;5:1024–6.

    Article  PubMed  CAS  Google Scholar 

  40. Dotzlaf JE, Yeh WK. Copurification and characterization of deacetoxycephalosporin C synthetase/hydroxylase from Cephalosporium acremonium. J Bacteriol. 1987;169:1611–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Higgens CE, Hamill RL, Sands TH, Hoehn MM, Davis NE. Letter: The occurrence of deacetoxycephalosporin C in fungi and streptomycetes. J Antibiot. 1974;27:298–300.

    Article  CAS  Google Scholar 

  42. Rabe P, Kamps J, Schofield CJ, Lohans CT. Roles of 2-oxoglutarate oxygenases and isopenicillin N synthase in beta-lactam biosynthesis. Nat Prod Rep. 2018;35:735–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Samson SM, et al. Cloning and expression of the fungal expandase hydroxylase gene involved in cephalosporin biosynthesis. Bio-Technol. 1987;5:1207. +

    CAS  Google Scholar 

  44. Kupka J, Shen YQ, Wolfe S, Demain AL. Studies on the ring-cyclization and ring-expansion enzymes of beta-lactam biosynthesis in Cephalosporium acremonium. Can J Microbiol. 1983;29:488–96.

    Article  PubMed  CAS  Google Scholar 

  45. Lejon S, Ellis J, Valegard K. The last step in cephalosporin C formation revealed: crystal structures of deacetylcephalosporin C acetyltransferase from Acremonium chrysogenum in complexes with reaction intermediates. J Mol Biol. 2008;377:935–44.

    Article  PubMed  CAS  Google Scholar 

  46. Schmitt EK, Hoff B, Kuck U. Regulation of cephalosporin biosynthesis. Adv Biochem Eng Biotechnol. 2004;88:1–43.

    PubMed  CAS  Google Scholar 

  47. Gutierrez S, Diez B, Montenegro E, Martin JF. Characterization of the Cephalosporium acremonium pcbAB gene encoding alpha-aminoadipyl-cysteinyl-valine synthetase, a large multidomain peptide synthetase: linkage to the pcbC gene as a cluster of early cephalosporin biosynthetic genes and evidence of multiple functional domains. J Bacteriol. 1991;173:2354–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Martin JF, Ullan RV, Casqueiro J. Novel genes involved in cephalosporin biosynthesis: the three-component isopenicillin N epimerase system. Adv Biochem Eng Biotechnol. 2004;88:91–109.

    PubMed  CAS  Google Scholar 

  49. Gutierrez S, Velasco J, Fernandez FJ, Martin JF. The Cefg gene of Cephalosporium-Acremonium is linked to the Cefef gene and encodes a Deacetylcephalosporin-C Acetyltransferase closely related to Homoserine O-Acetyltransferase. J Bacteriol. 1992;174:3056–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Teijeira F, Ullan RV, Guerra SM, Garcia-Estrada C, Vaca I, Martin JF. The transporter CefM involved in translocation of biosynthetic intermediates is essential for cephalosporin production. Biochem J. 2009;418:113–24.

    Article  PubMed  CAS  Google Scholar 

  51. Ullan RV, Teijeira F, Guerra SM, Vaca I, Martin JF. Characterization of a novel peroxisome membrane protein essential for conversion of isopenicillin N into cephalosporin C. Biochem J. 2010;432:227–36.

    Article  PubMed  CAS  Google Scholar 

  52. Ullan RV, Liu G, Casqueiro J, Gutierrez S, Banuelos O, Martin JF. The cefT gene of Acremonium chrysogenum C10 encodes a putative multidrug efflux pump protein that significantly increases cephalosporin C production. Mol Genet Genom. 2002;267:673–83.

    Article  CAS  Google Scholar 

  53. Gutierrez S, Fierro F, Casqueiro J, Martin JF. Gene organization and plasticity of the beta-lactam genes in different filamentous fungi. Anton Leeuw Int J G 1999;75:81–94.

    Article  CAS  Google Scholar 

  54. Liu L, Chen Z, Liu W, Ke X, Tian X, Chu J. Cephalosporin C biosynthesis and fermentation in Acremonium chrysogenum. Appl Microbiol Biotechnol. 2022;106:6413–26.

    Article  PubMed  CAS  Google Scholar 

  55. Skatrud PL, Queener SW. An electrophoretic molecular karyotype for an industrial strain of Cephalosporium acremonium. Gene. 1989;78:331–8.

    Article  PubMed  CAS  Google Scholar 

  56. Smith DJ, et al. Beta-Lactam antibiotic biosynthetic genes have been conserved in clusters in Prokaryotes and Eukaryotes. Embo J. 1990;9:741–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Pollegioni L, Rosini E, Molla G. Cephalosporin C acylase: dream and(/or) reality. Appl Microbiol Biotechnol. 2013;97:2341–55.

    Article  PubMed  CAS  Google Scholar 

  58. Bianchi D, Bortolo R, Golini P, Cesti P. Enzymatic transformation of cephalosporin C to 7-ACA by simultaneous action of immobilized d-amino acid oxidase and glutaryl-7-ACA acylase. Appl Biochem Biotech. 1998;73:257–68.

    Article  CAS  Google Scholar 

  59. Elander RP. Industrial production of beta-lactam antibiotics. Appl Microbiol Biotechnol. 2003;61:385–92.

    Article  PubMed  CAS  Google Scholar 

  60. Bush K, Bradford PA. beta-Lactams and beta-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med. 2016;6:a025247.

  61. Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: A focus on side chains and beta-lactam cross-reactivity. Pharmacy. 2019;7:103.

  62. Giamarellou H. Fourth generation cephalosporins in the antimicrobial chemotherapy of surgical infections. J Chemother. 1999;11:486–93.

    Article  Pub...

Comments

Post a Comment

Popular posts from this blog

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today

Image
Scabies is a skin condition that occurs as the result of a mite known as Sarcoptes scabiei. The rash that results from scabies may appear similar to other skin conditions, such as psoriasis, eczema, or contact dermatitis. In this article, we look at what a scabies rash looks like. We also look at other rashes that are similar in appearance and their treatment options. Scabies is a common condition that occurs as the result of an infestation of a microscopic skin mite called Sarcoptes scabiei. The mites burrow under the skin, causing intense itching and a rash. The Centers for Disease Control and Prevention (CDC) describes the rash as pimple-like. On darker skin, the rash may be more difficult to see, but a person should be able to feel it. According to DermNet, a scabies rash is varied in appearance, and may appear as: pimple-like on the limbs and trunk widespread or coin-shaped small blisters scales lesions in the armpits, groin, navel, areolas, scrotum, buttocks, and along the penil
Read more

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Image
Can I prevent a urinary tract infection? The following lifestyle changes can help prevent urinary tract infections: Practice good hygiene Practicing good hygiene is one of the best ways to help prevent UTIs. This is especially important if you have a vagina because your urethra is much shorter, and it's easier for E. coli to move from your rectum back into your body. Always wipe from front to back after a bowel movement (pooping) to avoid this. During your menstrual cycle, it's also a good idea to regularly change your period products, including pads and tampons. You should also avoid using any deodorants on your vagina. Drink plenty of fluids Drinking extra fluids — especially water — each day can help flush out bacteria from your urinary tract. Healthcare providers recommend drinking six to eight glasses of water daily. Change your peeing habits Peeing can play a big role in getting rid of bacteria from your body. Your pee is a waste product, and each time you empty your bla
Read more

Symtuza: Uses, side effects, alternatives, and more - Medical News Today

Image
The Food and Drug Administration (FDA) approves prescription drugs such as Symtuza to treat certain conditions. Symtuza is FDA-approved to treat HIV-1 in adults and children who weigh at least 40 kilograms (kg), which is about 88 pounds (lb). It's approved for people who: have just been diagnosed with HIV and haven't started treatment yet, OR are changing from another HIV treatment and: have been on a stable antiretroviral regimen for at least 6 months (this means you haven't had any changes to your HIV drugs for at least 6 months) have a viral load (the amount of HIV in your blood) that's less than 50 copies per milliliter (mL) have HIV that doesn't have mutations (changes) that could make it resistant (less likely to respond) to darunavir or tenofovir (two of the active drugs in Symtuza) HIV explained HIV stands for human immunodeficiency virus. There are two forms of this virus, HIV-1 and HIV-2. HIV-1 is the most common form. HIV is transmitted through body fluid
Read more